Literature DB >> 17435464

The Prader-Willi phenotype of fragile X syndrome.

Stephen T Nowicki1, Flora Tassone, Michele Y Ono, Jessica Ferranti, Marie Francoise Croquette, Beth Goodlin-Jones, Randi J Hagerman.   

Abstract

The Prader-Willi phenotype (PWP) of fragile X syndrome (FXS) is associated with obesity and hyperphagia similar to Prader-Willi syndrome (PWS), but without cytogenetic or methylation abnormalities at 15q11-13. Thirteen cases of PWP and FXS are reported here that were identified by obesity and hyperphagia. Delayed puberty was seen in 5 of 9 cases who had entered puberty, a small penis or testicles in seven of 13 cases, and infant hypotonia and/or a poor suck in seven of 13 cases. Autism spectrum disorder occurred in 10 of 13 cases, and autism was diagnosed in seven of 13 cases. We investigated cytoplasmic interacting FMR1 protein (CYFIP) expression, which is a protein that interacts with FMR1 protein (FMRP) because the gene for CYFIP is located at 15q11-13. CYFIP mRNA levels were significantly reduced in our patients with the PWP and FXS compared to individuals without FXS (p < .001) and also individuals with FXS without PWP (p = .03).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17435464     DOI: 10.1097/01.DBP.0000267563.18952.c9

Source DB:  PubMed          Journal:  J Dev Behav Pediatr        ISSN: 0196-206X            Impact factor:   2.225


  61 in total

Review 1.  Fragile X: leading the way for targeted treatments in autism.

Authors:  Lulu W Wang; Elizabeth Berry-Kravis; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 2.  Dendrite and spine modifications in autism and related neurodevelopmental disorders in patients and animal models.

Authors:  Verónica Martínez-Cerdeño
Journal:  Dev Neurobiol       Date:  2016-08-30       Impact factor: 3.964

3.  Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome.

Authors:  C A Hoeffer; E Sanchez; R J Hagerman; Y Mu; D V Nguyen; H Wong; A M Whelan; R S Zukin; E Klann; F Tassone
Journal:  Genes Brain Behav       Date:  2012-02-15       Impact factor: 3.449

4.  Opposing Post-transcriptional Control of InR by FMRP and LIN-28 Adjusts Stem Cell-Based Tissue Growth.

Authors:  Arthur Luhur; Kasun Buddika; Ishara Surangi Ariyapala; Shengyao Chen; Nicholas Samuel Sokol
Journal:  Cell Rep       Date:  2017-12-05       Impact factor: 9.423

5.  Metformin as targeted treatment in fragile X syndrome.

Authors:  A B C Dy; F Tassone; M Eldeeb; M J Salcedo-Arellano; N Tartaglia; R Hagerman
Journal:  Clin Genet       Date:  2017-09-25       Impact factor: 4.438

6.  Imitation in fragile X syndrome. Implications for autism.

Authors:  Marta Macedoni-Luksic; Laura Greiss-Hess; Sally J Rogers; David Gosar; Kerrie Lemons-Chitwood; Randi Hagerman
Journal:  Autism       Date:  2009-09-21

7.  Copy number variation and schizophrenia.

Authors:  David St Clair
Journal:  Schizophr Bull       Date:  2008-11-05       Impact factor: 9.306

Review 8.  Fragile X: a family of disorders.

Authors:  Weerasak Chonchaiya; Andrea Schneider; Randi J Hagerman
Journal:  Adv Pediatr       Date:  2009

9.  Aging in fragile X syndrome.

Authors:  Agustini Utari; Evan Adams; Elizabeth Berry-Kravis; Alyssa Chavez; Felicia Scaggs; Lily Ngotran; Antoniya Boyd; David Hessl; Louise W Gane; Flora Tassone; Nicole Tartaglia; Maureen A Leehey; Randi J Hagerman
Journal:  J Neurodev Disord       Date:  2010-05-12       Impact factor: 4.025

10.  Fragile X and autism: Intertwined at the molecular level leading to targeted treatments.

Authors:  Randi Hagerman; Gry Hoem; Paul Hagerman
Journal:  Mol Autism       Date:  2010-09-21       Impact factor: 7.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.